Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpaceSanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a "measured risk."Clinical DataImmunology & InflammationRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Clinical DataImmunology & InflammationRead full story Post navigation Previous: Sanofi immune drug hopeful posts mixed results in mid-stage testsNext: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026